Low-Dose Valganciclovir for CMV Prophylaxis after Lung Transplantation

Table 1

Baseline demographic data for the Valganciclovir study group.

Age, mean (years)	64
Gender: male/female	25/17
Indication for transplant, 𝑛 (%)
Chronic obstructive pulmonary disease	26 (62%)
Interstitial lung disease	4 (10%)
Idiopathic pulmonary fibrosis	6 (14%)
Cystic fibrosis	3 (7%)
Systemic sclerosis with pulmonary hypertension	1 (2%)
Alpha 1-antitrypsin deficiency	2 (4%)
CMV donor/recipient serostatus, 𝑛 (%)
D+/R+	28 (67%)
D+/R−	5 (12%)
D−/R+	5 (12%)
D−/R−	4 (9%)
Single/bilateral lung transplant	36/6
Acute rejection episodes	11 (26%)
Evidence of opportunistic infections
Aspergillus	12 (28%)
Mucor	2 (5%)
Cryptococcus	2 (5%)